ICR London Scientists Unveil Breakthrough Strategy Against T-ALL Protein LMO2

A team of scientists at The Institute of Cancer Research, London, has made a pivotal advancement against T-cell acute lymphoblastic leukaemia (T-ALL) by targeting the elusive protein LMO2. Marking a significant step forward, this novel approach might revolutionize treatment for this aggressive form of cancer and improve outcomes for patients. 

T-ALL, a rapid-growing cancer affecting mainly children and young adults, has seen improved survival rates with chemotherapy. However, relapse presents a persistent challenge. The protein LMO2, a major T-ALL driver, has evaded traditional drug targeting due to its inherently disordered structure, which lacks defined binding sites typical of other proteins. This study introduced a breakthrough platform designed to degrade LMO2, potentially turning the tide in T-ALL treatment. Supported by Blood Cancer UK and Cancer Research UK, researchers combined intracellular antibodies with proteolysis targeting chimeras (PROTACs) to hijack the cell’s waste disposal system. The engineered intracellular antibody fragment attaches to LMO2, flagging it for destruction by the cell’s recycling machinery. This approach not only has implications for T-ALL but could extend to other traditionally “undruggable” proteins.

The novel strategy to dismantle the oncogenic machinery by targeting LMO2 transforms the landscape of cancer drug discovery, promising new therapeutic avenues for tackling tough-to-treat leukaemias. This discovery not only represents a scientific triumph but also brings renewed hope for patients grappling with aggressive cancer forms.